A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC

NCT06280196 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

162

Enrollment

INDUSTRY

Sponsor class

Stopped The new regulatory developments have led us to conclude that a Phase 3 study is no longer necessary for the development and approval of BAT3306. As such, to ensure effective use of clinical resources, we are terminating this study.

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: BAT3306
DRUG: EU-Keytruda®
DRUG: US-Keytruda®
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Bio-Thera Solutions